



## MannKind Announces Settlement of Convertible Senior Notes

03/05/26

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- **MannKind Corporation (Nasdaq: MNKD)** today announced the settlement of the remaining \$36.3 million aggregate principal amount of 2.50% convertible senior notes, all of which were tendered for conversion prior to the maturity date of March 1, 2026. The settlement was made on March 4, 2026, with \$35.5 million in cash and 569,023 shares of MannKind common stock.

### About MannKind

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.

With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.

Learn more at [mannkindcorp.com](https://mannkindcorp.com).

MANNKIND is a registered trademark of MannKind Corporation.

### MannKind Contacts:

Investor Relations

Kate Miranda

(617) 921-5461

Email: [ir@mnkd.com](mailto:ir@mnkd.com)

### Media Relations

Christie Iacangelo

(818) 292-3500

Email: [media@mnkd.com](mailto:media@mnkd.com)



Source: MannKind